Conditions: Late Onset Alzheimer Disease
Keywords: Alzheimer's disease Positron emission tomography Biomarker Brain amyloid plaque load
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 161
Healthy volunteers: no

Brief summary:
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive decline and Alzheimer's disease progression. The driving hypothesis of the study is that amyloid beta in the brain as measured by positron emission tomography positivity is associated with the onset of cognitive decline associated with late onset Alzheimer's disease.

Detailed description:
This project is a sub-study of the Washington Heights-Inwood Community Aging Project, which is a multidisciplinary, epidemiological study of Alzheimer's disease and related neurodegenerative disorders. We will obtain positron emission tomography scans and simultaneous x-ray computed tomography scans using Florbetaben from Bayer on a selection of ongoing participants who will be selected on the basis of change in plasma levels of amyloid beta over time. Approximately 200 participants will receive scans beginning in 2009 and in the 2010-2012 assessment wave and then again in a 2014-2015 assessment wave. Our intention is to examine whether uptake of Florbetaben in the brain is associated with decline in cognition over the 10 years prior to the PET scan.

Arms:
arm 1: BAY 94-9172 PET/CT

Interventions: intervention 1: BAY 94-9172 (Florbetaben)
Intervention descriptions: intervention 1: Measure of brain amyloid load using BAY 94-9172 PET/CT

Protocol document: